Billions saved because FDA didn't rush approval of Alzheimer's drug

The U.S. Food and Drug Administration's decision not to rush approval for Eli Lilly's experimental Alzheimer's treatment solanezumab - a drug that turned out to be ineffective - may have saved American taxpayers as much as $100 billion over the past four years, an analysis concludes.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news